Mdma och autism- rätten till den inre resan.

Det är tid att börja tala klarspråk om MDMA som en PTSD behandling, och som möjligt bidrag till personlig utveckling hos individer med autism och dess spektrum. Om Psykiatrin skall ha en framtid är det som assistans vid utfarskandet av medvetande…

mdma1

For decades, the empathogenic drug known as MDMA, or 3,4-Methylenedioxy-N-methamphetamine, has been a subject often associated with the early 2000′s rave culture, far extended from association with therapy and other medicinal applications. Unfortunately, being that MDMA is a heavily controlled drug in many countries, proper research for therapeutic applications has been extremely limited, until recently.

Under årtionden har den empatogena drogen kallad MDMA, eller 3,4-metylendioxi-N-metamfetamin, ofta varit förknippats med det tidiga 2000 och ravekulturen och sällan assosierats med behandling och andra medicinska tillämpningar. Tyvärr är MDMA ett starkt kontrollerad läkemedel i många länder varvid ordentlig forskning för terapeutiska tillämpningar varit ytterst begränsad, tills nyligen.

MAPS (The Multidisciplinary Association for Psychedelic Studies) broke news this year of the preliminary steps of a ground-breaking new study which is looking at treating autistic patients who suffer from social anxiety with MDMA.

MAPS The Multidisciplinary Association for Psychedelic Studies (ungefär Tvärvetenskaplig sammanslutning för forskning på psykadelika) tog i år de preliminära första stegen i en banbrytande ny studie som tittar på behandling av autistiska patienter som lider av social ångest med MDMA.

Autistic Therapeutic Interventions

Conventional medication and therapy interventions fail to help treat Autistic patients, could MDMA assisted therapy be a possible solution?
Conventional medication and therapy interventions fail to help treat Autistic patients with social anxiety, could MDMA-assisted therapy be a possible solution?
Although the complex set of distinctions between autistic and non-autistic neurology is not fully understood, we do know that the subjective experience of autistic people tends to be more intense and chaotic than that of non-autistic individuals, as the impact of information processing tends to be both stronger and less predictable on both the sensorimotor and cognitive levels.

Terapeutisk intervention vid autistiska tillstånd

Då konventionella mediciner och terapier misslyckas med att behandla Autistiska patienter med social ångest, kan då MDMA assisterad terapi vara en möjlig lösning?
Även om de komplexa distinktionerna mellan autistiska och icke-autistiska neurologi inte är helt klarlagd, vet vi att den subjektiva upplevelsen av autistiska människor tenderar att vara mer intensiv och kaotisk än för icke-autistiska individer, och att effekterna av informationsbehandling tenderar att vara både starkare och mindre förutsägbar på både sensomotoriska och kognitiva nivåer.

 

According to MAPS, “the early lives of autistic individuals often involve repeated traumatic experiences of social rejection and abuse (by family, professionals, peers, and others). As a result, many autistic individuals suffer from diagnosed conditions such as anxiety (particularly social anxiety), post-traumatic stress disorder (PTSD), and depression, as well as difficulties with interpersonal connection and social adaptability.”

Enligt MAPS, ”involverar de tidiga åren av autistiska individers liv ofta upprepade traumatiska upplevelser av social utstötning och misshandel (genom familj, personal, kollegor och andra), vilket resulterar i att många autistiska individer lider av diagnostiserade sjukdomar såsom ångest (särskilt social ångest), posttraumatiskt stressyndrom (PTSD) och depression, samt svårigheter med sociala interaktioner och social anpassningsförmåga. ”

For the most part, conventional medications are ineffective in treating stress related issues among autistic people, and because autistic people have difficulties building rapport with therapists, traditional psychotherapy also fails to treat the issue. Therefore, new treatment options are being explored in order to provide autistic individuals with an improved quality of life.

För det mesta, är konventionella läkemedel ineffektiva vid behandling av stressrelaterade problem bland autistiska människor och eftersom människor med autism sällan anknyter till terapeuter och/eller teraputers problemformuleringar så saknar också traditionell psykoterapi relevans. Därför utforskas nu nya behandlingsalternativ för att ge autistiska individer en förbättrad livskvalitet.

Why MDMA?

MDMA has a unique set of psychoactive properties which makes it a viable adjunct to conventional psychotherapy.
First synthesized in 1912, MDMA has been a popular topic of discussion due to its unique psychoactive properties. It is considered an entheogen, a substance which produces spiritual, transcendent experiences for its users. “Its unique pharmacological properties make it a viable adjunct as a therapy for social anxiety in autistic patients”, states the MAPS official study website. Some of these properties include:

Decreased feelings of fear

Increased feelings of well-being

Increased sociability

Increased interpersonal trust

Alert state of consciousness

Increased awareness of some domains of empathy

MDMA-assisted therapy combines the techniques of traditional psychotherapy along with the controlled administration of MDMA in order to enhance the therapy’s effectiveness.

The therapeutic method will be adapted from therapy techniques that have shown clinical effectiveness in adults with an Autism Spectrum diagnosis. Best practices from clinical research on MDMA-assisted psychotherapy for PTSD also will be applied.

Varför MDMA?

MDMA har en unik uppsättning av psykoaktiva egenskaper som utgör ett viktigt komplment till konventionell psykoterapi.
Sedan MDMA syntetiserades 1912, har MDMA varit ett populärt diskussionsämne på grund av dess unika psykoaktiva egenskaper. Den betraktas som en entheogen, ett ämne som ger andlig, transcendenta upplevelser hos brukarna.
”Dess unika farmakologiska egenskaper gör den till en livskraftig komplementär terapivid social oro hos autistiska patienter”, säger MAPS officiella studie hemsida.

Några av dessa egenskaper är:

Minskade känslor av rädsla

Ökad känsla av välbefinnande

Ökad sällskaplighet

Ökad tillit

Alert medvetandetillstånd

Ökad medvetenhet om vissa domäner av empati

MDMA assisterad terapi kombinerar teknikerna av traditionell psykoterapi tillsammans med styrd administration av MDMA i syfte att öka terapins effektivitet.
Den terapeutiska metoden kommer att anpassas utifrån terapimetoder som har visat klinisk effekt hos vuxna med Autism Spectrum diagnos. De bästa tillämpningarna från klinisk forskning på MDMA assisterad psykoterapi för PTSD också kommer att tillämpas.

MAPS states that the method will focus on developing a therapeutic relationship with the subjects that will provide a permissive setting in which to learn and practice social skills.

MAPS konstaterar att metoden kommer att fokusera på att utveckla en terapeutisk relation med de ämnen som ger en tillåtande miljö att lära sig och träna på sociala färdigheter.

For more information regarding the physical, chemical, and pharmacological properties of MDMA, click HERE.

För mer info klicka på länken ovan.

A Determined Team of Researchers

EC7R9979
Alicia Danforth, Ph.D., co-investigator of the study. Alicia has been studying psychedelic assisted therapy since 2006.
grob_charles2_med
Charles S. Grobs, M.D., will be heading the study looking at MDMA assisted therapy in treating social anxiety among autistic patients.
The study is headed by Charles S. Grob, M.D., Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center, as well as Professor of Psychiatry and Pediatrics at the University of California, Los Angeles School of Medicine. Grob’s co-investigator is Alicia Danforth Ph.D, research associate at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

En beslutsam forskargrupp

“The question is: ‘Can we re-engage this area in a responsible, objective way to explore methods of a treatment?’ ” Grob said to the Daily News. “But to do so in a responsible way, unlike what happened in the ’60s.”

Each study participant (who are all adults) who receives the active drug will be given a small dose of 75 to 125 milligrams, and a male and female researcher will sit with them throughout the six to eight hour process, during which they will be closely monitored.

”Frågan är:” Kan vi återuppta detta område på ett ansvarsfullt och objektivt sätt för att utveckla behandlingsmetoder” sa Grob till Daily News. ”Men göra det på ett ansvarsfullt sätt, till skillnad från hur det gick till på 60-talet.”

Varje studiedeltagare (som alla är vuxna) som tar emot det aktiva läkemedlet kommer att få en liten dos på 75-125 mg, och en manlig och kvinnlig forskare kommer att sitta med dem under en hela sex till åtta timmars process, vilken nogrant kommer att övervakas.

“We try to optimize ‘set and setting’ in order to ensure strong, safe parameters,” Grob said. “I suppose that is ultimately derived from the shamanic model.”

”Vi försöker att optimera situationen och att säkerställa starka, säkra parametrar”, säger Grob. ”Jag antar att detta ursprungligen kan härledas från en shamansk modell.”

Grobs is one of the growing number of scientists and researchers who believe that psychedelics such as psilocybin, ayahuasca, and MDMA hold the answers for treatment of various mental illnesses and addictions. His resume definitely isn’t shy of psychedelic research- since the 1990′s Grobs has been involved with rare studies examining the benefits of ayahusaca, and psilocybin. In both of his studies, Grobs found that psychedelics are helpful in ways that conventional medicine is not.

Grobs är en del av ett växande antal vetenskapsmän och forskare som tror att det i psykedelika såsom psilocybin, ayahuasca, och MDMA går finna lösningar till behandling av olika psykiska sjukdomar och missbruk. Hans CV är definitivt inte blygsamt. Av psykedelisk forsknings- sedan 1990-talet har Grobs varit involverad i ovanliga studier som undersökt fördelarna med ayahusaca och psilocybin. I båda studierna fann Grobs fann att psykedelia är behjälpligt på plan där skolmedicinen misslyckas.

”We’re looking for something to facilitate positive, ongoing change,” Grob said. “You can’t take an autistic person and make them un-autistic, but you can treat the overwhelming social anxiety.”

”Vi letar efter något att medverka till en positiv och pågående förändring,” säger Grob. ”Du kan inte ta en autistisk människa och göra hen o-autistisk, men du kan behandla den överväldigande sociala ångesten.”

A Triumphant Return

The study of psychedelics blew-up in the 1950′s as curious researchers began exploring their clinical applications. Scientists and researchers of the time were astounded by the mind-altering properties of psychedelics and wondered if they could help treat psychological conditions such as depression, anxiety, and even schizophrenia. Even the military became involved with psychedelic testing, for instance they used MDMA as an interrogation tool in their MKUltra program.[3]

En triumferande återkomst

Studier av psykedelier entrade scenen på 1950-talet då nyfikna forskare började utforska s kliniska tillämpningar.
Den tidens vetenskapsmän och forskare var förbluffade av psykadelikans sinnesförändrande egenskaper och hur de kunde hjälpa till att behandla psykiska sjukdomar såsom depression, ångest och även schizofreni. Även militären blev involverad med psykedeliska tester, till exempel de använde MDMA som förhörsverktyg i deras mkultra (sic!) program.

The 1960′s propagated a new perspective on psychedelics as they became the forefront of the counter-culture movement which was sweeping the Western world at the time. People were waking up to government nonsense and taking a stand against war, specifically the Vietnam War. Therefore, it wasn’t long until the Controlled Substances Act was passed in 1970, placing most psychedelics under strict control. This, along with the promotion of drug propaganda through the media, silenced most psychedelic research for decades to come.

1960-talet propagerades nya perspektiv på psykedelia då de blev spetsen för den motkultur och en rörelse som svepte över västvärlden . Människor ifrågasatte regeringen nonsens och tag ställning mot krig i almännhet och vietnamkriget i synnerhet. Det varade inte länge förrän Controlled Substances Act antogs 1970,viken placerade merparten f psykedelia under strikt kontroll. Detta, tillsammans med att främjandet läkemedelsreklam och antidrogpropaganda via media tystade den psykedeliska forskningen i årtionden framöver.

LSD became central to the counterculture movement of the 1960′s, as peace and love were advocated by the public to end the Vietnam war.
LSD became central to the counterculture movement of the 1960′s, as peace and love were advocated by the public to end the Vietnam war.
MDMA was a late bloomer and didn’t start gaining popularity until the 1970′s, where clinical psychologists and therapists began implementing MDMA use during client sessions. MDMA was found to enhance communication during clinical sessions, reduce patients’ psychological defenses, and increase capacity for therapeutic introspection.

LSD blev central för motkulturens av 1960-talet, som förespråkade fred och kärlek och allmänheten agiterade för avslutande av vietnamkriget.
MDMA var en late bloomer och började inte öka i popularitet förens 1970-talet, där kliniska psykologer och terapeuter började med användning av MDMA under klientsessioner. MDMA befanns förbättra kommunikationen under kliniska sessioner, minska patienternas psykologiska försvar, och öka kapaciteten för terapeutisk introspektion.

During the 1980′s, the use of MDMA moved into the clubber and rave culture, where party-goers would use the stimulant to dance through long hours of the night. This popularity among the young fueled the DEA to classify MDMA as a schedule I drug in 1985, inhibiting MDMA research along with it.

Now, we see the return of interest in MDMA-assisted therapy. Charles Grobs hopes the negative stigma of the drug can be amended with adherence to strict scientific models, which Grob has designed based on the historic use of hallucinogenics in “shamanic society.”

Now that research with these drugs has resumed, the next hurdle is getting financing for such studies. Grob and Danforth will not be able to finish the current MDMA study unless they receive more funds.

Learn how you can donate HERE.

Under 1980-talet flyttade användningen av MDMA in i klubb och ravekulturen, där deltagare kom att använda stimulantia dansa genom långa nätter inpå småtimmarna. Dess popularitet bland de unga gav DEA tillfället att göra MDMA till ett klassifierat narkotiskt preparat 1985, vilket också sköt MDMA-forskningen i sank.

Nu ser vi intresset för MDMA assisterad terapi återkomma ochCharles Grobs hoppas den negativa stigmatiseringen av läkemedlet kan ändras med iakttagandet av strikta vetenskapliga modeller som utformats utifrån den historiska användningen av hallucinogener i ”shamansk samhället.”

Nu när forskningen med dessa läkemedel har återupptagits, är nästa hinder att finansieringen av dessa studier. Grob och Danforth kommer inte att kunna avsluta den pågående MDMA studien om de inte får mer pengar.

Återkommer med mer översättningar när datorfittan slutar flippa och leka glödhett fanskap. MVH Red.

More To Come?
These are exciting times indeed, with the latest push to explore the promising therapeutic and medicinal benefits of various plants and psychedelics such as cannabis, LSD, ayahuasca, ibogaine, MDMA, and more. We’ve already seen how ayahuasca and ibogaine are showing remarkable results in treating severe drug addiction. We’re also witnessing how concentrated forms of medical cannabis is eradicating cancer and other life threatening diseases.

Perhaps this was how it was intended to be all along, nature being the cure for mankind’s ailments and collective insanity. The next few years will prove to be innovative and ground-breaking nonetheless, as more truth comes to light about the powerful healing capabilities of plants and psychedelics, so stay tuned.

What are your thoughts about the use of MDMA-assisted therapy? Do you think that psychedelics should be examined more for their medicinal and therapeutic properties? Share with us below!

References:

http://www.maps.org/

http://www.maps.org/news-letters/v12n3/12305dob.html

Martin A. Lee, Acid Dreams: The Complete Social History of LSD: the CIA, the Sixties, and Beyond. 1985, Grove Press.

http://www.dailynews.com/health/20140802/county-harbor-ucla-medical-researcher-studies-using-hallucinogens-mdma-to-help-adults-on-the-autism-spectrum

MAPS Email Newsletter:
”I Did In Three Sessions What I
Couldn’t Do In Thirty, Forty Years”
May 9, 2014
Dear friends and supporters,

FEATURED The Verge, ”Ecstatic States” | April 29, 2014
Watch now
Last week, The Verge debuted their impactful all-new report Ecstatic States, including a 13-minute segment about how MDMA-assisted psychotherapy is transforming the lives of veterans, sexual assault survivors, and others with posttraumatic stress disorder (PTSD). One of the interview subjects is Vietnam veteran Bob Walker, who says, ”I did in three sessions what I couldn’t do in 30, 40 years.”

Our international series of Phase 2 studies of MDMA-assisted psychotherapy for PTSD is advancing at an unprecedented pace, with new subjects enrolled and treated in South Carolina, Colorado, and Israel. We’re also adding a new co-therapist team to our upcoming study in Canada.

The Spring 2014 MAPS Bulletin: Special Edition on Psychedelics and Education is now available online. The issue includes 15 all-new original articles about how we teach future psychedelic psychotherapists, which educational paths to take when embarking on a career in psychedelic research, how students are working to end the global War on Drugs, and much more.

In the May 2014 edition of the Multidisciplinary Association for Psychedelic Studies (MAPS) Email Newsletter, you’ll also learn:

The National Institute on Drug Abuse (NIDA) tells us that it does not have the marijuana needed for our study, contradicting their previous claim and causing more delays
Our New Zealand observational study of ibogaine-assisted therapy for opiate addiction enrolls its final subject, and data collection is finished for our completed study in Mexico
Longtime supporter Timothy Butcher leaves a $1.9 million bequest to MAPS, making a new study possible and expanding our ability to support psychedelic research worldwide
Iraq veteran Tony Macie hosts a popular Ask Me Anything on reddit, answering over 250 questions about his recovery from PTSD after participating in our study of MDMA-assisted psychotherapy
Get daily updates and stay connected with the psychedelic and medical marijuana research community by joining us on Facebook, Twitter, and YouTube. The conversation is always expanding.
The advancement of our mission depends on the hard work and financial support of those who want to see psychedelics and marijuana reintegrated into our clinics and culture. This edition of the MAPS Email Newsletter is dedicated to the legacy and inspiration of our friends, family, and colleagues who have passed on, and who continue to inspire us with their work and their words.

always upward,

Brad Burge
MAPS Director of Communications and Marketing
Treating PTSD with MDMA-Assisted Psychotherapy

Boulder: Sixth and Seventh Subjects Treated, Amendment Submitted to FDA and IRB
U.S. Veterans: 17th Subject Enrolled and Treated
Israel: Fourth Subject Enrolled
Medical Marijuana Research

NIDA Admits It Doesn’t Have Marijuana Required for Research, Causing More Delays for PTSD Study
Ibogaine-Assisted Therapy For Drug Addiction

Mexico: Data Entry Completed for Observational Study
New Zealand: 14th and Final Subject Enrolled
Support MAPS

When We Work Together, We Change How the World Sees Psychedelics
Precious Moments Artist Timothy Butcher Leaves $1.9 Million Bequest to MAPS
Media

Special Issue of Journal of Psychoactive Drugs on Psychedelic Research and Therapy
The Verge, Tony Macie on reddit, Huffington Post, Business Insider, and more…
MAPS Store

LSD: Problem Child and Wonder Drug Documentary DVD
Limited Edition Dichroic Glass Pendants featuring MAPS Logo
Events

Women’s Visionary Congress: May 30-June 1, Petaluma, CA
Ongoing: Psychedelic Science: Evolver Learning Lab Webinar: May 7-June 11
More News

Are You an Academic Researcher Doing Clinical Research? Here’s How You Can Help
The Visionary World of H.R. Giger by Stanislav Grof: Coming from MAPS in March 2015

In Ecstatic States, an all-new report from The Verge, Vietnam veteran Bob Walker shares how MDMA-assisted psychotherapy helped him recover from PTSD: ”I did in three sessions what I couldn’t do in thirty, forty years.”Watch now…
TREATING PTSD WITH MDMA-ASSISTED PSYCHOTHERAPY

1. Boulder: Sixth and Seventh Subjects Treated, Amendment Submitted to FDA and IRB

On April 18, 2014, the sixth subject was treated in our ongoing study of MDMA-assisted psychotherapy for PTSD in Boulder, Colorado. The seventh subject was enrolled on March 27, and received the first MDMA-assisted psychotherapy session on May 2. Additionally, on May 1, we submitted a revised protocol for review to the Institutional Review Board proposing to increase the study size from 17 to 23 subjects , and on May 2 we submitted the revised protocol to the U.S. Food and Drug Administration. This study is investigating the safety and effectiveness of MDMA-assisted psychotherapy for subjects with chronic, treatment-resistant PTSD resulting from sexual assault, violent crime, war, or any other cause. Download the study protocol | Learn more…
$742,000 estimated study cost • $213,000 raised • $529,000 still needed

2. U.S. Veterans: 17th Subject Enrolled and Treated

On May 6, 2014, the 17th subject was treated in our ongoing study of MDMA-assisted psychotherapy in 24 U.S. veterans, fire fighters, and police officers with chronic, treatment-resistant PTSD. This subject was enrolled on April 9. This subject has also enrolled in our new sub-study of the physiological effects of MDMA-assisted psychotherapy, which will examine heart rate variability (HRV) and functional magnetic resonance imaging (fMRI) and explore correlations with clinical outcomes. Overall goals for this study include (1) gathering evidence for the safety and effectiveness of MDMA-assisted psychotherapy in people suffering from war-related trauma; (2) comparing the effectiveness of the treatment for people with war-related trauma versus for people with trauma related to sexual abuse, assault, and other causes; (2) comparing different doses of MDMA; and (3) increasing awareness and support for our work by assisting a publicly recognized population. Learn more…
$1,376,000 estimated study cost • $1,074,000 raised • $302,000 still needed

3. Israel: Fourth Subject Enrolled

On April 16, 2014, the fourth subject was enrolled in our ongoing Israeli study of MDMA-assisted psychotherapy for 10 subjects with chronic, treatment-resistant PTSD. Goals for this study include (1) gathering evidence for the safety and effectiveness of MDMA-assisted psychotherapy for subjects with PTSD mostly related to war and terrorism, (2) comparing the effectiveness of different doses of MDMA for therapy and double-blind, (3) working in direct association with the Israeli Ministry of Health, and (4) exploring the use of MDMA-assisted psychotherapy in other cultural contexts. Learn more…
$492,000 estimated study cost • $43,000 raised • $449,000 still needed

Learn more about MDMA-assisted psychotherapy on or at mdmaptsd.org.

MEDICAL MARIJUANA RESEARCH

4. NIDA Admits It Doesn’t Have Marijuana Required for Research, Causing More Delays for PTSD Study

On April 17, 2014, the National Institute on Drug Abuse (NIDA) informed MAPS that it does not have the marijuana needed for our study. This was completely unexpected as it contradicts NIDA’s written claim over three years ago that they did have a supply of marijuana containing the balanced THC/CBD ratio needed for our study. We designed our protocol around that variety in order to gather information about the relative risks and benefits of THC and CBD in veterans with chronic, treatment-resistant PTSD. It now looks like there will be another delay of at least half a year while we wait for NIDA to produce the marijuana we need for our study. Learn more….
$885,000 estimated study budget • $885,000 still needed

IBOGAINE-ASSISTED THERAPY FOR DRUG ADDICTION

Image: Christopher Hansen
5. Mexico: Data Entry Completed for Observational Study

On April 11, 2014, data entry was completed for our observational study of ibogaine-assisted therapy for opioid dependence in Mexico. Data cleanup will begin soon in preparation for submitting the results for publication in a peer-reviewed scientific journal. In this study, Principal Investigator Thomas Kingsley Brown, Ph.D., observed the long-term effects of ibogaine treatment for individuals undergoing treatment for opioid dependence at an independent clinic in Mexico. Learn more….

6. New Zealand: 14th and Final Subject Enrolled

On April 27, 2014, the 14th and final subject was enrolled in our nearly completed New Zealand observational study of ibogaine-assisted treatment for opioid dependence. Since July 2012, Principal Investigator Geoff Noller, Ph.D., has been collecting follow-up data from subjects undergoing treatment at an independent ibogaine center in New Zealand. Eight participants have completed the study including the long-term follow-up. Data from this study will be compared to the results of our completed observational study in Mexico. Learn more…

Learn about our current Funding Priorities.

SUPPORT MAPS

7. When We Work Together, We Change How the World Sees Psychedelics

The Spring 2014 MAPS Bulletin: Special Edition on Psychedelics and Education is now available online, featuring 15 original articles spanning psychedelic science, medicine, and culture.
In April 2014, 198 people contributed $387,550 to increase scientific knowledge about psychedelics and communicate that knowledge to the wider public. Riverstyx Foundation generously pledged $240,000 to add 12 subjects to our now 24-subject planned study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness study to be led by Principal Investigator Phil Wolfson, MD, in Marin, Calif. Philip Payson also donated $53,889 from a charitable remainder trust he inherited recently. Special thanks to the Threshold Foundation for their $22,725 grant for MDMA-assisted psychotherapy for PTSD research, and to the Michael & Anita Siegal Family Foundation for a $4,000 grant for our Israeli MDMA-assisted psychotherapy study. Our Canadian supporters also stepped up at our April events in Vancouver, giving roughly $40,000, including pledges of $20,000 from Steve Chapman, $3,000 from Kolin Lymworth, and $3,000 from an anonymous donor, all for our Vancouver MDMA-assisted psychotherapy study. We are also grateful for a $5,000 donation out of a $25,000 pledge from Carey & Claudia Turnbull, and a $5,000 donation from Sir Ivan Wilzig, both for MDMA-assisted psychotherapy for PTSD. Thanks goes to the Tinnitus Research Initiative Foundation for $10,000 grant for our tinnitus research, to Philip Wolfson for a $2,000 donation, to Michael Divine for $1,420, and to Thomas Huntington for $1,000. On behalf of our fiscal sponsors, we also thank those who contributed to Bluelight, Ayahuasca Association, Ethnobotanical Stewardship Council, and the Global Ibogaine Therapist Alliance. Our heartfelt gratitude goes to the 178 donors who gave between $1 and $999 for general support, and for MDMA-assisted psychotherapy drug development in the U.S., Israel, and Canada. When we work together, giving in the ways and amounts that work best for each of us, we change how the world sees psychedelics. Thank you.

Help us make psychedelics and marijuana into prescription medicines—donate today!

Tim Butcher (1967-2012)
8. Precious Moments Artist Timothy Butcher Leaves $1.9 Million Bequest to MAPS

Funding for research into the therapeutic uses of psychedelics and medical marijuana increased significantly in April 2014, when we announced that MAPS will receive a generous $1.9 million bequest from the estate of longtime MAPS supporter Timothy Butcher. Starting in 1996, Tim donated over $155,000 to support MAPS’ work, though his bequest came as a surprise to us. ”Tim was passionate about our mission,” says MAPS Founder and Executive Director Rick Doblin, Ph.D. ”Unbeknownst to me, Tim decided to include MAPS in his will in a characteristically modest and humble manner. As we expand our work, Tim’s bequest provides crucially needed support.” Tim cared most about the use of MDMA-assisted psychotherapy in people struggling with end-of-life issues. Tim’s bequest has enabled MAPS to begin working to start a new MDMA-assisted psychotherapy study in subjects with anxiety from life-threatening illnesses.
View the press release | Learn about bequests…

MEDIA

9. Special Issue of Journal of Psychoactive Drugs on Psychedelic Research and Therapy

Volume 26, Issue 1 of the peer-reviewed Journal of Psychoactive Drugs highlights some of the results and ongoing research into LSD, MDMA, and other psychedelic drugs. The special issue brings together contributions from scientists around the world, including:

History and Future of MAPS by Amy Emerson, Linnae Ponté, Lisa Jerome, and Rick Doblin
Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry by Ben Sessa
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program by George Greer, Charles Grob, and Adam Halberstadt
The complete Table of Contents and abstracts are available online here.
10. The Verge, Tony Macie on reddit, Huffington Post, Business Insider, and more…

PRESS RELEASE: Precious Moments Artist Timothy Butcher Leaves $1.9 Million Bequest to MAPS | view
MAPS | April 29, 2014

FEATURED The Verge: Ecstatic States Mini-Documentary | watch
Lessley Anderson | April 29, 2014

FEATURED reddit: MDMA-Assisted Psychotherapy Study Participant Tony Macie Hosts Q&A on reddit | view
Tony Macie | April 16, 2014

Huffington Post: Veteran Explains How MDMA Helped Heal His Postwar Trauma | view
Anna Almendrala | April 16, 2014

Business Insider: Veteran: Ecstasy Drug Saved Me From My Battle With PTSD | view
Jeremy Bender | April 16, 2014

Military.com via Houston Chronicle: In Study, Ecstasy Shows Promise for Treating PTSD | view
Kyrie O’Connor | May 6, 2014

Alternet: 5 Amazing Things Scientists Have Discovered About Psychedelics | view
April Short | April 11, 2014

Crushplate: The Bright Future Of Clinical LSD Research: A Conversation With MAPS | listen
NPR Staff | March 9, 2014

Motherboard: These Short Online Psychedelic Courses Will Bend Your Mind | view
DJ Pangburn | April 16, 2014

The Daily Beast: Are the Feds Hoarding Pot? | view
Steven Wishnia | April 22, 2014

Washington Times: Veterans Push to Test Marijuana as a Life-Saving Treatment for Crippling PTSD | view
Jacqueline Klimas | April 22, 2014

Explore MAPS in the Media for more psychedelic and medical marijuana research news.

MAPS STORE

11. LSD: Problem Child and Wonder Drug Documentary DVD

LSD: Problem Child and Wonder Drug
Documentary DVD

60 Minutes | Released 2008

LSD: Problem Child and Wonder Drug captures the fascinating story of LSD as told by discoverer Albert Hofmann at his 100th birthday conference. With interviews and presentations by Rick Doblin, Alex Grey, Ralph Metzner, Carl Ruck, Goa Gil, and others, this historic message from the father of LSD is a timeless relic and an immediate source of inspiration.

$25.00 | Now available

12. Limited Edition Dichroic Glass Pendants featuring MAPS Logo

Limited Edition Dichroic Glass Pendants
featuring MAPS Logo

Show your support for psychedelic science with pride and style with this unique dichroic glass pendant. Each unique handmade pendant contains subtle variations with a shimmering MAPS logo embedded in sturdy blown glass. We have only commissioned a limited number of these, so get yours while supplies last. These make spectacular gifts.
Made with love by Atlantis Arising Inc./Dichroic Alchemy.

$25.00 | Now available

All purchases from the MAPS Store support our research and education projects.

EVENTS

13. Women’s Visionary Congress: May 30-June 1, Petaluma, CA

The eighth annual Women’s Visionary Congress will take place from May 30-June 1st, 2014, at the Institute of Noetic Sciences (IONS) stunning EarthRise Retreat Center in Petaluma, California. The gathering will include presentations from visionary researchers, healers, activists and artists from the U.S., Canada and Mexico. Registration ($350) includes lodging, meals, and WVC membership. Day passes also available. Buy tickets…

14. Ongoing: Psychedelic Science: Evolver Learning Lab Webinar: May 7-June 11

Brad Burge of MAPS has invited some of the leading experts in psychedelic science and medicine to help you understand, integrate, and learn to use the most recent research from this transformative field. You will be part of the discussion over five weekly sessions, able to ask your questions on camera, just like a Skype call. A portion of proceeds supports MAPS’ psychedelic and medical marijuana research and education projects. The course started on May 7, but you can still register for access to upcoming sessions and past session recordings.

View our Event Calendar for more upcoming events.

MORE NEWS

15. Are You an Academic Researcher Doing Clinical Research? Here’s How You Can Help

As our clinical program continues moving forward, we have decided to partner with Medrio, a leading clinical trial data management service. The Medrio system will enhance our ability to work with clinical data in real time and improve our data quality control processes. Medrio has agreed to give us free access in exchange for referrals to university or pharmaceutical industry researchers who might benefit from the software. To learn about this system for yourself and help us cover costs, take a free tour of Medrio and request a free test database to explore. Taking the tour does not require any purchase or agreement—the only requirements are current affiliation with an accredited academic institution and that you are able to consider a system like Medrio for your own clinical research. If you are interested in taking the tour, please take a minute to confirm your academic affiliation. We will verify your email address and send a follow-up email with instructions for how to take the tour. Take the tour…

16. The Visionary World of H.R. Giger by Stanislav Grof: Coming from MAPS in March 2015

This year, Swiss publisher Nachtschatten Verlag released a bilingual Swiss hardcover edition of pioneering transpersonal psychiatrist Stanislav Grof’s H.R. Giger and the Zeitgeist of the Twentieth Century. The forthcoming English-only MAPS edition, The Visionary World of H.R. Giger: The Contributions of Consciousness Research to the Understanding of Art, will include a full-length version of Grof’s essay on the contributions of psychedelic and consciousness research to the understanding of art, additional artwork, and an original foreword. The Visionary World of H.R. Giger will be released by MAPS in March 2015.

Looking for more ways to get involved? Check out our Student Resources page!

Creative Commons 2014 MAPS 1215 Mission St Santa Cruz, CA 95060-9989 USA tel:+1 831-429-MDMA (6362) fax: +1 831-429-6370 [email protected]